Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Decreases By 24.4%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 657,200 shares, a drop of 24.4% from the March 31st total of 868,800 shares. Based on an average daily volume of 388,300 shares, the days-to-cover ratio is presently 1.7 days.

Aligos Therapeutics Stock Down 4.4 %

Shares of ALGS stock opened at $0.78 on Friday. Aligos Therapeutics has a one year low of $0.54 and a one year high of $1.38. The stock has a fifty day moving average price of $0.91 and a 200 day moving average price of $0.76.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Tuesday, March 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $3.20 million. Aligos Therapeutics had a negative return on equity of 116.41% and a negative net margin of 607.03%. On average, research analysts forecast that Aligos Therapeutics will post -0.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Aligos Therapeutics by 1.6% during the third quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company’s stock valued at $755,000 after acquiring an additional 15,905 shares during the period. Newtyn Management LLC lifted its holdings in shares of Aligos Therapeutics by 2.2% during the third quarter. Newtyn Management LLC now owns 920,000 shares of the company’s stock valued at $687,000 after acquiring an additional 20,000 shares during the period. Opaleye Management Inc. bought a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $861,000. Altitude Crest Partners Inc. bought a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $1,889,000. Finally, Armistice Capital LLC bought a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $4,538,000. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).